With the rise of more transmissible variants and the reduced efficacy of outpatient monoclonal antibody therapies, the market for oral antivirals is expected to climb to new heights this year.…
The Middle East and Africa, combined, represent the world’s fifth largest regional pharma market. According to IQVIA’s recent figures, most of the largest markets grew, although slowly due to COVID…
Weeks after a mosquito forced the recall of 765,000 doses of Moderna’s vaccine manufactured in Spain, the country’s top medicines regulator called for new inspection procedures, praised the loyalty of…
While the pharma industry provides the vital medicines needed to treat diseases and keep populations healthy, it is also responsible for carbon emissions of an intensity almost 55 percent higher…
With global ambitions, Atrys Health, a publicly traded Spanish health-tech company, is betting on telediagnosis and last-generation radiotherapy to lead the precision medicine race, not missing the Big Data opportunities…
When the FDA gave Novartis the historic green light for Kymriah – the first gene therapy approved in the United States – in 2017, the agency declared that it was…
At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of…
Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
See our Cookie Privacy Policy Here
